Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Polyzois Makras

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Acta Bio-Medica : Atenei Parmensis|October 27, 2022
Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisitedMaria P Yavropoulou, Athanasios D Anastasilakis, Ploutarchos Tzoulis, et al.
SICOT-J|March 6, 2026
Glucagon-like peptide-1 receptor agonists in orthopaedicsAndreas F Mavrogenis, Pavlos Altsitzioglou, Sotirios Pililis, et al.
European Journal of Endocrinology|March 12, 2017
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatmentAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, et al.
Bone Reports|September 20, 2021
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patientsPolyzois Makras, Panagiotis Petrikkos, Athanasios D Anastasilakis, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 2, 2023
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injectionPolyzois Makras, Maria P Yavropoulou, Stergios A Polyzos, et al.
Endocrine|November 25, 2017
Irisin in metabolic diseasesStergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, et al.
Journal of Bone and Mineral Metabolism|June 10, 2015
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, et al.
European Journal of Endocrinology|June 28, 2024
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?Athanasios D Anastasilakis, Maria P Yavropoulou, Andrea Palermo, et al.
Bone|October 8, 2018
Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatmentElena Tsourdi, Polyzois Makras, Tilman D Rachner, et al.
Current Diabetes Reports|October 8, 2025
The Effects of Obesity and Weight Loss Interventions on Bone Health: A Narrative ReviewAndrea Palermo, Elena Tsourdi, Maria P Yavropoulou, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Acta Bio-Medica : Atenei Parmensis|October 27, 2022
Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisitedMaria P Yavropoulou, Athanasios D Anastasilakis, Ploutarchos Tzoulis, et al.
SICOT-J|March 6, 2026
Glucagon-like peptide-1 receptor agonists in orthopaedicsAndreas F Mavrogenis, Pavlos Altsitzioglou, Sotirios Pililis, et al.
European Journal of Endocrinology|March 12, 2017
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatmentAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, et al.
Bone Reports|September 20, 2021
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patientsPolyzois Makras, Panagiotis Petrikkos, Athanasios D Anastasilakis, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 2, 2023
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injectionPolyzois Makras, Maria P Yavropoulou, Stergios A Polyzos, et al.
Endocrine|November 25, 2017
Irisin in metabolic diseasesStergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, et al.
Journal of Bone and Mineral Metabolism|June 10, 2015
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, et al.
European Journal of Endocrinology|June 28, 2024
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?Athanasios D Anastasilakis, Maria P Yavropoulou, Andrea Palermo, et al.
Bone|October 8, 2018
Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatmentElena Tsourdi, Polyzois Makras, Tilman D Rachner, et al.
Current Diabetes Reports|October 8, 2025
The Effects of Obesity and Weight Loss Interventions on Bone Health: A Narrative ReviewAndrea Palermo, Elena Tsourdi, Maria P Yavropoulou, et al.
Pageof 13